Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status

European Journal of Cancer（2023）

引用 1|浏览25

暂无评分

摘要

•First cohort of poor PS mRCC treated with front line ICI-based combination therapy.•The survival outcomes were inferior to that reported in pivotal trials.•No significant differences in ORR, PFS or OS were seen between NI and AP.•Both NI and AP were well tolerated without significant differences between them.

查看译文

关键词

Renal cell carcinoma,Poor performance status,Combination therapy,Immune checkpoint inhibitors,Immunotherapy,Kidney cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要